Blar i forfatter "Andersen, Gry"

Viser treff 1-2 av 2

    • Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis 

      Norum, Jan; Antonsen, Margaret Aarag; Tollåli, Geir; Al-Shibli, Khalid; Andersen, Gry; Svanqvist, Kristin-Helene; Helbekkmo, Nina (Journal article; Tidsskriftartikkel; Peer reviewed, 2017-07-29)
      1 Norum J, et al . ESMO Open 2017; 2 :e000222. doi:10.1136/esmoopen-2017-000222 Open Access Abstr A ct Background P embrolizumab is a new drug approved in several countries for second-line therapy in non-small cell lung cancer (NSCLC) being programmed cell death ligand (PD-L1) positive. This drug has a high cost, and the cost- effectiveness ratio has been debated. Patients ...

    • PET-CT in the-subarctic region of Norway 2010-2013. At the edge of what is possible? 

      Norum, Jan; Søndergaard, Ursula; Traasdahl, Erik; Nieder, Carsten; Tollåli, Geir; Andersen, Gry; Sundset, Rune (Journal article; Tidsskriftartikkel; Peer reviewed, 2015-08-28)
      Background It is challenging to obtain a similar access to positron emission tomography/computed tomography (PET-CT) within the whole region served. In the subarctic and arctic region of Norway, significant distances, weather conditions and seasonable darkness have been challenging when the health care provider has aimed for a high quality PET-CT service with similar availability to all inhabitants. ...